Amarin stock plunges to 52-week low of $0.4 amid market challenges

Published 12/03/2025, 19:40
Amarin stock plunges to 52-week low of $0.4 amid market challenges

In a turbulent turn of events, Amarin Corporation plc (NASDAQ:AMRN) stock has tumbled to a 52-week low, touching a distressing price level of $0.4. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company maintains a healthy current ratio of 3.23, suggesting strong short-term liquidity. This significant drop underscores a challenging period for the biopharmaceutical company, which has seen its share value erode by a staggering 52.38% over the past year. With a market capitalization of $193.49M and revenue declining 25.25% over the last twelve months, investors have been closely monitoring Amarin’s performance. The company’s beta of 1.83 indicates higher volatility than the broader market, while InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels. The 52-week low serves as a critical indicator of the pressures faced by Amarin, as market participants consider the company’s strategic moves to recover from this downturn. For deeper insights, investors can access comprehensive analysis and 8 additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Amarin Corporation reported its fourth-quarter 2024 earnings, showcasing a better-than-expected performance in terms of earnings per share (EPS) but a decline in revenue compared to the previous year. The company’s EPS came in at -0.02, surpassing the forecast of -0.05, while total net revenue for the quarter was $62.3 million, down from $74.7 million in Q4 2023. Despite the positive earnings surprise, Amarin’s stock experienced a decline in premarket trading. The revenue decline was primarily driven by a significant drop in U.S. product revenue, which fell to $44.2 million from $64.9 million in the previous year. Meanwhile, European product revenue increased to $4 million, reflecting positive growth in international markets. Amarin maintains a strong cash position with $294 million and no debt, offering a solid financial foundation. Additionally, the company secured patent protection for Vascepa in Europe until 2039, ensuring future market opportunities. Looking ahead, Amarin plans to focus on maximizing U.S. revenue efficiency and expanding its presence in European and global markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.